/BLPH

BLPH Stock - Bellerophon Therapeutics, Inc.

Q: What is the analyst price target for BLPH?

Analyst price target information is not currently available for BLPH.

Q: What is BLPH's market cap?

Market capitalization information is not currently available for BLPH.

Healthcare|Biotechnology|NASDAQ

$0.01-36.84%

$0.01 (-36.84%) • Dec 18

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BLPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.70

52W High$0.10

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-65,000	$-102,000	$-147,000	$-348,000	$-362,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-22,384,000	$-20,161,000	$-26,276,000	$-17,473,000	$-27,880,000
Net Income	$-19,831,000	$-17,756,000	$-24,728,000	$-13,267,000	$2.81M
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.08	$-1.87	$-3.17	$-2.95	$0.65

Company Overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Visit Website

Earnings History & Surprises

BLPH

Beat Rate

76%

Last 17 quarters

Avg Surprise

+24.1%

EPS vs Estimate

Beats / Misses

13/3

1 met exactly

Latest EPS

$-0.16

Q4 2023

EPS Surprise History

Q1 22

+25.0%

$-0.45vs$-0.60

Q2 22

-7.3%

$-0.59vs$-0.55

Q3 22

+29.5%

$-0.43vs$-0.61

Q4 22

+10.2%

$-0.53vs$-0.59

Q1 23

-10.4%

$-0.53vs$-0.48

Q2 23

+131.3%

$0.15vs$-0.48

Q3 23

0.0%

$-0.42vs$-0.42

Q4 23

+63.6%

$-0.16vs$-0.44

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Sep 23, 2024	—	—	—	—
Q2 2024	Jun 6, 2024	$-0.42	—	—	—
Q1 2024	Mar 1, 2024	$-0.33	—	—	—
Q4 2023	Nov 14, 2023	$-0.44	$-0.16	+63.6%	✓ BEAT
Q3 2023	Aug 14, 2023	$-0.42	$-0.42	0.0%	= MET
Q2 2023	May 15, 2023	$-0.48	$0.15	+131.3%	✓ BEAT
Q1 2023	Mar 31, 2023	$-0.48	$-0.53	-10.4%	✗ MISS
Q4 2022	Nov 14, 2022	$-0.59	$-0.53	+10.2%	✓ BEAT
Q3 2022	Aug 15, 2022	$-0.61	$-0.43	+29.5%	✓ BEAT
Q2 2022	May 11, 2022	$-0.55	$-0.59	-7.3%	✗ MISS
Q1 2022	Mar 31, 2022	$-0.60	$-0.45	+25.0%	✓ BEAT
Q4 2021	Nov 15, 2021	$-0.63	$-0.49	+22.2%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.66	$-0.36	+45.5%	✓ BEAT
Q2 2021	May 11, 2021	$-0.71	$-0.58	+18.3%	✓ BEAT
Q1 2021	Mar 11, 2021	$-0.90	$-0.84	+6.7%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.82	$-0.84	-2.4%	✗ MISS
Q3 2020	Aug 5, 2020	$-0.68	$-0.51	+25.0%	✓ BEAT
Q2 2020	May 11, 2020	$-1.02	$-0.89	+12.7%	✓ BEAT
Q2 2020	Apr 6, 2020	$-1.05	$-0.89	+15.2%	✓ BEAT
Q4 2019	Nov 6, 2019	$-1.20	$-0.90	+25.0%	✓ BEAT

Frequently Asked Questions about BLPH

What is BLPH's current stock price?

Bellerophon Therapeutics, Inc. (BLPH) is currently trading at $0.01 per share. The stock has moved -36.84% today.

What is the analyst price target for BLPH?

No analyst price targets are currently available for this stock.

What sector is Bellerophon Therapeutics, Inc. in?

Bellerophon Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is BLPH's market cap?

Bellerophon Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does BLPH pay dividends?

No, Bellerophon Therapeutics, Inc. does not currently pay a dividend to shareholders.